Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics (ARQTResearch Report) today and set a price target of $58.00. The company’s shares closed last Friday at $17.41, close to its 52-week low of $14.16.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.2% and a 28.6% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Avrobio, and uniQure.

Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $46.50.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $38.49 and a one-year low of $14.16. Currently, Arcutis Biotherapeutics has an average volume of 176.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.

Read More on ARQT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed